Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Equillium, Inc.EQ · Entity 6560 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Equillium, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-05-27 | Direct | 70,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
1 source rowRow 1 · 2023-11-08 · Other · Disposed 618,894 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $266.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 332 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $266.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 5,401 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $161.16 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 1,044 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $161.16 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 31,506 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $94.29 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 635 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $94.29 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 29,865 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $107.18 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 1,207 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $107.18 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 38,793 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 207 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-08 · Disposition to issuer · Disposed 45,293 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-11-08 · Disposition to issuer · Disposed 889 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-11-08 · Disposition to issuer · Disposed 12,811 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $99.66 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-11-08 · Disposition to issuer · Disposed 17,700 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2021 Filed Jan 5, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 632 | $24.70 | $15,610.40 |
DisclosureSEC source: 0001104659-21-001125 · tm211606-7_4seq1.xml · nonDerivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,056 F3 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 25,065 | $24.70 | $619,105.50 |
DisclosureSEC source: 0001104659-21-001125 · tm211606-7_4seq1.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,688 F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 41,236 | $24.70 | $1,018,529.20 |
DisclosureSEC source: 0001104659-21-001125 · tm211606-7_4seq1.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,753 F1 · shares: Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 772 | $42.08 | $32,485.76 |
DisclosureSEC source: 0001104659-20-112319 · tm2032461d4_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,517 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 772 | $46.52 | $35,913.44 |
DisclosureSEC source: 0001104659-20-081441 · tm20240737_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,289 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001209191-20-031275 · doc4.xml · derivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-19 F1 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 19:06 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 568 | $58.40 | $33,171.20 |
DisclosureSEC source: 0001104659-20-043289 · tm2014981d7_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,061 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 19:07 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 17,700 | $0.00 Strike: $99.66 | $0.00 |
DisclosureSEC source: 0001104659-20-007268 · tm205922d9_4.xml · derivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 Underlying: Common Stock · 17,700 shares Expires 2030-01-23 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 19:07 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-007268 · tm205922d9_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,629 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,166 | $123.92 | $144,490.72 |
DisclosureSEC source: 0001104659-20-001086 · tm201209d3_4.xml · nonDerivative · entry 4 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,829 F3 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock awards previously granted to the reporting person. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 100 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001104659-20-001086 · tm201209d3_4.xml · derivative · entry 6 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,084 Underlying: Common Stock · 100 shares Expires 2022-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,131 | $123.92 | $140,153.52 |
DisclosureSEC source: 0001104659-20-001086 · tm201209d3_4.xml · nonDerivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,995 F2 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 100 | $125.00 | $12,500.00 |
DisclosureSEC source: 0001104659-20-001086 · tm201209d3_4.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,126 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 100 | $21.50 | $2,150.00 |
DisclosureSEC source: 0001104659-20-001086 · tm201209d3_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 417 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001104659-19-076863 · tm1928364d2_4.xml · derivative · entry 4 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,184 Underlying: Common Stock · 417 shares Expires 2022-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 417 | $125.00 | $52,125.00 |
DisclosureSEC source: 0001104659-19-076863 · tm1928364d2_4.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,126 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 26, 2019 Filed Dec 30, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 417 | $21.50 | $8,965.50 |
DisclosureSEC source: 0001104659-19-076863 · tm1928364d2_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 15,557 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · derivative · entry 11 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,601 Underlying: Common Stock · 15,557 shares Expires 2022-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 19,880 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · derivative · entry 10 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,880 shares Expires 2021-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 35,437 | $100.00 | $3,543,700.00 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · nonDerivative · entry 6 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,126 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 15,557 | $21.50 | $334,475.50 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · nonDerivative · entry 5 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 19,880 | $8.67 | $172,294.00 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · nonDerivative · entry 4 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 14,524 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · derivative · entry 9 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,880 Underlying: Common Stock · 14,524 shares Expires 2021-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 39 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · derivative · entry 8 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39 shares Expires 2020-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 14,563 | $100.00 | $1,456,300.00 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · nonDerivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,126 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 14,524 | $8.67 | $125,875.15 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 39 | $8.67 | $338.00 |
DisclosureSEC source: 0001104659-19-068397 · tm1924027d1_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,547 | $65.87 | $101,900.89 |
DisclosureSEC source: 0001144204-19-047220 · tv530561_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,126 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock awards previously granted to the reporting person. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,548 | $79.17 | $122,555.16 |
DisclosureSEC source: 0001144204-19-033811 · tv524730_form4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,673 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock awards previously granted to the reporting person. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:41 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001209191-19-036807 · doc4.xml · derivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,547 | $111.50 | $172,490.50 |
DisclosureSEC source: 0001144204-19-018074 · tv517179_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,221 F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock awards previously granted to the reporting person. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 13,700 | $0.00 Strike: $110.80 | $0.00 |
DisclosureSEC source: 0001144204-19-002141 · tv511182_4.xml · derivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2029-01-16 F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2019. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-002141 · tv511182_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,768 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2019. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 19:03 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 1,537 | $100.79 | $154,914.23 |
DisclosureSEC source: 0001144204-19-000501 · tv510192_form4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,268 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 27,606 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · derivative · entry 10 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39 Underlying: Common Stock · 27,606 shares Expires 2020-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,988 | $103.29 | $205,332.57 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · nonDerivative · entry 8 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,805 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.025 to $103.57, inclusive. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 7,839 | $102.61 | $804,373.90 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · nonDerivative · entry 7 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,793 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.025 to $103.02, inclusive. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 7,949 | $101.48 | $806,686.78 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · nonDerivative · entry 6 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,632 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.955, inclusive. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 9,830 | $100.38 | $986,735.40 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · nonDerivative · entry 5 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,581 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 27,606 | $8.67 | $239,252.92 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · nonDerivative · entry 4 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 22,394 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · derivative · entry 9 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,645 Underlying: Common Stock · 22,394 shares Expires 2020-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 3,521 | $101.13 | $356,088.24 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · nonDerivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,805 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.285, inclusive. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 18,873 | $100.38 | $1,894,496.27 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,326 F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 22,394 | $8.67 | $194,082.08 |
DisclosureSEC source: 0001144204-18-060579 · tv507484_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 2,049 | $126.46 | $259,116.54 |
DisclosureSEC source: 0001144204-18-052403 · tv503771_4.xml · nonDerivative · entry 4 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,805 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. F2 · balance_after: In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4. Read SEC document |
| July 01, 2018 Filed Oct 3, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 2,051 | $83.91 | $172,099.41 |
DisclosureSEC source: 0001144204-18-052403 · tv503771_4.xml · nonDerivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,805 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. F2 · balance_after: In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4. Read SEC document |
| April 09, 2018 Filed Apr 9, 2018 19:36 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | PurchaseCommon Stock | 7,812 | $64.00 | $499,968.00 |
DisclosureSEC source: 0001144204-18-019836 · tv490675_form4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,564 Read SEC document |
| April 01, 2018 Filed Oct 3, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 2,050 | $61.52 | $126,116.00 |
DisclosureSEC source: 0001144204-18-052403 · tv503771_4.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,805 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. F2 · balance_after: In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4. Read SEC document |
| February 05, 2018 Filed Feb 22, 2018 21:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOptions to Purchase Common Stock · Derivative | 45,500 | $0.00 Strike: $58.74 | $0.00 |
DisclosureSEC source: 0001144204-18-010361 · tv486825_4.xml · derivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-02-05 F1 · derivative.exercise_date: 25% of the shares of common stock underlying this option will vest on January 1, 2019, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2022 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| January 01, 2018 Filed Oct 3, 2018 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Tax withholdingCommon Stock | 3,609 | $58.42 | $210,837.78 |
DisclosureSEC source: 0001144204-18-052403 · tv503771_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,805 F1 · shares: Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock. F2 · balance_after: In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.